liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel
Linköping University, Department of Medical and Health Sciences, Clinical Pharmacology. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Cell Biology. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Oncology. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre of Surgery and Oncology, Department of Oncology UHL.
Department of Oncology Sahlgrenska Academy at Göteborg University, Gothenburg.
Show others and affiliations
2008 (English)In: Journal of Pharmaceutical Sciences, ISSN 0022-3549, E-ISSN 1520-6017, Vol. 97, no 6, 2045-2048 p.Article in journal, Letter (Other academic) Published
Abstract [en]

P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel. Recently, the G1199T/A polymorphism in the ABCB1 gene was shown to be important for the function of P-gp as well as for the resistance to several chemotherapeutic agents in vitro. We analyzed the allelic distribution of the G1199T/A and other polymorphisms in exons 11 and 12 of the ABCB1 gene in ovarian cancer patients treated with paclitaxel and carboplatin in order to evaluate their predictive value in vivo. The SNPs C1236T, G1199T/A, and A1308G were determined using Pyrosequencing in 51 patients with advanced ovarian cancer and correlated to the progression free survival. The G1199T/A SNP was found to affect the progression free survival. Although only two heterozygous (G/A) patients were found their mean progression free survival was only 2 months as compared to 19 months for the wild-type patients. This is in accordance with the higher resistance for the 1199A genetic variant found in vitro. Genotyping of the ABCB1 gene may be important for determining the tumor resistance to paclitaxel and provide useful information for individualized therapy.  

Place, publisher, year, edition, pages
John Wiley & Sons, 2008. Vol. 97, no 6, 2045-2048 p.
Keyword [en]
ABCB1; paclitaxel; ovarian cancer; G1199T/A
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-43261DOI: 10.1002/jps.21169ISI: 000256324300007PubMedID: 17828752Local ID: 73219OAI: diva2:264120

This is a pre-peer-reviewed version of: Henrik Green, Peter Söderkvist, Per Rosenberg, Grörgy Horvath and Curt Peterson, ABCB1 G1199A Polymorphism and Ovarian Cancer Response to Paclitaxel, 2008, Journal of Pharmaceutical Sciences, (97), 6, 2045-2048. which is published in final form at: Copyright: John Wiley and Sons, Ltd

Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2012-11-01

Open Access in DiVA

fulltext(179 kB)546 downloads
File information
File name FULLTEXT01.pdfFile size 179 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Green, HenrikSöderkvist, PeterRosenberg, PerPeterson, Curt
By organisation
Clinical PharmacologyFaculty of Health SciencesCell BiologyOncologyDepartment of Oncology UHL
In the same journal
Journal of Pharmaceutical Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 546 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 166 hits
ReferencesLink to record
Permanent link

Direct link